Discussion
The U.S. Food and Drug Administration (FDA) has approved an oral pellet version of Orladeyo (berotralstat) for teens and adults with hereditary angioedema (HAE), expanding access to a formulation previously available only for young children. Developed by Biocryst Pharmaceuticals, the once-daily preventive treatment was previously approved as…